Cargando…
Outcome of highly active antiretroviral therapy in HIV- infected Indian children
BACKGROUND: With the advent of highly active antiretroviral therapy (HAART), HIV infection has become a chronic condition in children with improved survival and quality of life. Reports on long term effectiveness of non-nucleoside reverse transcriptase inhibitor based HAART in HIV-infected children...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297378/ https://www.ncbi.nlm.nih.gov/pubmed/25539905 http://dx.doi.org/10.1186/s12879-014-0701-2 |
_version_ | 1782353137304076288 |
---|---|
author | Mukherjee, Aparna Shah, Nipam Singh, Ravinder Vajpayee, Madhu Kabra, Sushil K Lodha, Rakesh |
author_facet | Mukherjee, Aparna Shah, Nipam Singh, Ravinder Vajpayee, Madhu Kabra, Sushil K Lodha, Rakesh |
author_sort | Mukherjee, Aparna |
collection | PubMed |
description | BACKGROUND: With the advent of highly active antiretroviral therapy (HAART), HIV infection has become a chronic condition in children with improved survival and quality of life. Reports on long term effectiveness of non-nucleoside reverse transcriptase inhibitor based HAART in HIV-infected children in developing countries are limited. METHODS: A chart review was conducted and children who received at least six months of HAART between 2004–2011 at All India Institute of Medical Sciences (AIIMS), Delhi were included. The clinical, immunological and virological responses to HAART were documented. Factors predicting non-adherence and non-response to treatment were described. RESULTS: One seventy five children (boys: 74.9%) were included in the study, with a median follow up of 43 (IQR:17, 68) months. The median age at diagnosis was 119 (IQR: 75, 156) months. The median CD4 count at start of HAART was 340 cells/μL (IQR: 185,704), which increased to 924 cells/μL (IQR:591,1278) at 48 months after HAART and plateaued at 749 (IQR: 542,1056) cells/ μL after 90 months of therapy. The weight for age (WAZ) and height for age (HAZ) z score both showed improvement with time after HAART initiation [baseline: WAZ −2.8 (IQR:-4,-1.6), HAZ −2.1 (IQR:-3.4,-0.69); at 42 months of therapy: WAZ −1.2 (IQR:-2.1, 0.01), HAZ −0.75(IQR:-1.6,-0.37)]. Adverse events were reported in 21 (12%) children. Non-adherence to therapy, treatment failure and death were noted in 35 (20%), 9 (5.1%) and 6 (3.4%) children respectively. CONCLUSIONS: Our experience shows that HAART in HIV-infected children is effective, safe and is associated with good immunological and virological response as well as improvement in growth parameters. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0701-2) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4297378 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42973782015-01-18 Outcome of highly active antiretroviral therapy in HIV- infected Indian children Mukherjee, Aparna Shah, Nipam Singh, Ravinder Vajpayee, Madhu Kabra, Sushil K Lodha, Rakesh BMC Infect Dis Research Article BACKGROUND: With the advent of highly active antiretroviral therapy (HAART), HIV infection has become a chronic condition in children with improved survival and quality of life. Reports on long term effectiveness of non-nucleoside reverse transcriptase inhibitor based HAART in HIV-infected children in developing countries are limited. METHODS: A chart review was conducted and children who received at least six months of HAART between 2004–2011 at All India Institute of Medical Sciences (AIIMS), Delhi were included. The clinical, immunological and virological responses to HAART were documented. Factors predicting non-adherence and non-response to treatment were described. RESULTS: One seventy five children (boys: 74.9%) were included in the study, with a median follow up of 43 (IQR:17, 68) months. The median age at diagnosis was 119 (IQR: 75, 156) months. The median CD4 count at start of HAART was 340 cells/μL (IQR: 185,704), which increased to 924 cells/μL (IQR:591,1278) at 48 months after HAART and plateaued at 749 (IQR: 542,1056) cells/ μL after 90 months of therapy. The weight for age (WAZ) and height for age (HAZ) z score both showed improvement with time after HAART initiation [baseline: WAZ −2.8 (IQR:-4,-1.6), HAZ −2.1 (IQR:-3.4,-0.69); at 42 months of therapy: WAZ −1.2 (IQR:-2.1, 0.01), HAZ −0.75(IQR:-1.6,-0.37)]. Adverse events were reported in 21 (12%) children. Non-adherence to therapy, treatment failure and death were noted in 35 (20%), 9 (5.1%) and 6 (3.4%) children respectively. CONCLUSIONS: Our experience shows that HAART in HIV-infected children is effective, safe and is associated with good immunological and virological response as well as improvement in growth parameters. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-014-0701-2) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-24 /pmc/articles/PMC4297378/ /pubmed/25539905 http://dx.doi.org/10.1186/s12879-014-0701-2 Text en © Mukherjee et al.; licensee BioMed Central. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Mukherjee, Aparna Shah, Nipam Singh, Ravinder Vajpayee, Madhu Kabra, Sushil K Lodha, Rakesh Outcome of highly active antiretroviral therapy in HIV- infected Indian children |
title | Outcome of highly active antiretroviral therapy in HIV- infected Indian children |
title_full | Outcome of highly active antiretroviral therapy in HIV- infected Indian children |
title_fullStr | Outcome of highly active antiretroviral therapy in HIV- infected Indian children |
title_full_unstemmed | Outcome of highly active antiretroviral therapy in HIV- infected Indian children |
title_short | Outcome of highly active antiretroviral therapy in HIV- infected Indian children |
title_sort | outcome of highly active antiretroviral therapy in hiv- infected indian children |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4297378/ https://www.ncbi.nlm.nih.gov/pubmed/25539905 http://dx.doi.org/10.1186/s12879-014-0701-2 |
work_keys_str_mv | AT mukherjeeaparna outcomeofhighlyactiveantiretroviraltherapyinhivinfectedindianchildren AT shahnipam outcomeofhighlyactiveantiretroviraltherapyinhivinfectedindianchildren AT singhravinder outcomeofhighlyactiveantiretroviraltherapyinhivinfectedindianchildren AT vajpayeemadhu outcomeofhighlyactiveantiretroviraltherapyinhivinfectedindianchildren AT kabrasushilk outcomeofhighlyactiveantiretroviraltherapyinhivinfectedindianchildren AT lodharakesh outcomeofhighlyactiveantiretroviraltherapyinhivinfectedindianchildren |